Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Once-daily Oral Direct Factor Xa Inhibitor Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism. The Einstein-Extension Study

NCT00439725 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00439725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00439725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Once-daily Oral Direct Factor Xa Inhibitor Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism. The Einstein-Extension Study
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2007
Completion date
September 30, 2009
Enrollment
1,197 (actual)
Sites
322

Conditions

As the registry lists them; a condition with its own page is linked.

venous thromboembolism